ARS Investment Partners LLC Has $11.66 Million Stock Holdings in Biohaven Ltd. $BHVN

ARS Investment Partners LLC increased its position in shares of Biohaven Ltd. (NYSE:BHVN) by 11.2% in the 1st quarter, Holdings Channel.com reports. The fund owned 1,378,828 shares of the company’s stock after buying an additional 139,228 shares during the quarter. ARS Investment Partners LLC’s holdings in Biohaven were worth $11,665,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. PNC Financial Services Group Inc. increased its position in Biohaven by 113.7% in the 3rd quarter. PNC Financial Services Group Inc. now owns 2,383 shares of the company’s stock worth $36,000 after purchasing an additional 1,268 shares during the last quarter. IFP Advisors Inc raised its stake in shares of Biohaven by 55.4% during the 4th quarter. IFP Advisors Inc now owns 4,069 shares of the company’s stock worth $46,000 after purchasing an additional 1,450 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Biohaven by 178.4% during the 4th quarter. EverSource Wealth Advisors LLC now owns 4,031 shares of the company’s stock valued at $46,000 after buying an additional 2,583 shares during the last quarter. Arax Advisory Partners lifted its holdings in shares of Biohaven by 943.3% during the 4th quarter. Arax Advisory Partners now owns 4,914 shares of the company’s stock valued at $55,000 after buying an additional 4,443 shares during the last quarter. Finally, Leonteq Securities AG bought a new stake in shares of Biohaven in the 4th quarter valued at approximately $78,000. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Biohaven Price Performance

Shares of NYSE:BHVN opened at $13.56 on Friday. The stock has a market capitalization of $2.04 billion, a P/E ratio of -2.39 and a beta of 1.35. The business has a 50-day moving average of $10.35 and a two-hundred day moving average of $10.62. Biohaven Ltd. has a fifty-two week low of $7.48 and a fifty-two week high of $18.57. The company has a debt-to-equity ratio of 1.87, a current ratio of 7.41 and a quick ratio of 7.41.

Biohaven (NYSE:BHVN) last issued its quarterly earnings data on Monday, May 4th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.02). On average, equities research analysts predict that Biohaven Ltd. will post -3.07 EPS for the current fiscal year.

Analysts Set New Price Targets

BHVN has been the topic of a number of research reports. Canaccord Genuity Group started coverage on Biohaven in a report on Monday, April 13th. They issued a “buy” rating and a $21.00 price objective on the stock. Wall Street Zen cut shares of Biohaven from a “sell” rating to a “strong sell” rating in a research note on Sunday, April 26th. Royal Bank Of Canada decreased their target price on shares of Biohaven from $23.00 to $22.00 and set an “outperform” rating for the company in a research report on Tuesday, May 5th. HC Wainwright restated a “neutral” rating and set a $10.00 price target on shares of Biohaven in a research note on Tuesday, May 26th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Biohaven in a research note on Tuesday, June 2nd. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Biohaven presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.27.

About Biohaven

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.